SCHEMBL2321845

SCHEMBL2321845

Cc1cc(F)ccc1-c1cc2c(nn1)C1CCC2C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
SLC6A4 P31645 6/20 0.34
HTR1A P08908 1/20 0.34
DRD1 P21728 1/20 0.34
SLC6A2 P23975 1/20 0.34
HTR1B P28222 1/20 0.34
HTR2A P28223 1/20 0.34
SLC6A3 Q01959 1/20 0.34
OPRL1 P41146 4/20 0.33
MAP3K14 Q99558 1/20 0.33
TLR8 Q9NR97 1/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA4 P43681 1/20 0.32
GRM2 Q14416 1/20 0.32
ABL1 P00519 1/20 0.32
OXTR P30559 1/20 0.32
AVPR1A P37288 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2321830 0.86 LMNA (0.37) CHRNB2CHRNA4
SCHEMBL2322937 0.86 CYP11B1 (0.37) CYP11B1CYP11B2SLC6A4HTR1ADRD1
SCHEMBL2322920 0.84 NISCH (0.37) SLC6A4HTR1ADRD1SLC6A2HTR1B
SCHEMBL2325997 0.84 NOTUM (0.38) SLC6A4SLC6A3CHRNB2CHRNA4ABL1
SCHEMBL2322849 0.82 RAB9A (0.43) CYP3A4
SCHEMBL2325391 0.82 AR (0.40) SLC6A4HTR1ADRD1SLC6A2HTR1B
SCHEMBL2325039 0.81 CDK9 (0.40) HTR2A
SCHEMBL2322258 0.79 NOTUM (0.34) SLC6A4HTR1ADRD1SLC6A2HTR1B
SCHEMBL2326805 0.77 CNR2 (0.39) HTR2A
SCHEMBL2323614 0.76 NPC1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP claimed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US claimed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 CYP11B1 8/4885CYP11B2 15/4885SLC6A4 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.